An increasing number of epidemiological studies have suggested that, the anti-TNF-α therapies, including adalimumab, etanercept and adalimumab, are utilized to treat different peripheral nerve diseases, including chronic inflammatory demyelinating polyneuropathy, Miller Fisher syndrome, Guillain–Barré syndrome, mononeuropathy multiplex, multifocal motor neuropathy accompanied by conduction block, and axonal sensorimotor polyneuropathy [54]. This evidence concerns the gene TNF and Miller Fisher syndrome.